Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

AGM Statement

20 Sep 2007 07:01

Angle PLC20 September 2007 For Immediate Release 20 September 2007 ANGLE plc ('ANGLE' or the 'Company') AGM Statement At the Annual General Meeting of ANGLE plc today, Hance Fullerton, retiringChairman, will make the following statement: "ANGLE has made a strong start to the year, continuing to trade in line with theexpectations for the year outlined at our Preliminary Results announcement on 5July. Solid progress has been made in both of our key operating divisions. Our Management services business is now trading profitably and is expected todeliver at least £0.4 million profit for the year. In addition to successfullyimplementing £1m of annualised cost savings, ANGLE has also secured asignificant new contract win with the Innovation Lincolnshire Outreach Programmewhich, as announced on 27 June, will generate £0.9m of revenue for the Companyover a 21 month period. The Group will continue to pursue further such contractsin order to drive revenue growth and broaden its exposure to a pipeline ofpotentially high-value IP opportunities. Solid progress has also been made within our Ventures division. Evidence ofsuccessful value creation has been demonstrated, as announced on 5 July, througha £4 million profit from the gain in fair value of portfolio company Geomerics.Furthermore, in line with our current strategy, operating costs in this divisionhave also been reduced by an estimated £1.3 million on an annualised basis. As previously announced, I am retiring following today's Annual General Meetingand Garth Selvey is succeeding me as non-executive Chairman. I would like tothank the Chief Executive, other directors and senior management for all theirsupport over the years. I look forward to hearing of ANGLE's success in thefuture." Andrew Newland, Chief Executive will add: "I would like to take this opportunity to thank Hance for all his hard work anddedication to ANGLE over the years. Under his stewardship, the Group hasdeveloped from a start-up business to an established leader in IPcommercialisation. We wish Hance all the best for a long and enjoyableretirement and sincerely thank him for his outstanding contribution to ANGLE." Enquiries: ANGLE plc Andrew Newland, Chief Executive 01483 295830Ian Griffiths, Finance Director Collin Stewart Europe Limited 020 7523 8350Mark Connelly Scott Harris 0207 653 0030Stephen Scott, James O'Shaughnessy, Harry Dee Buchanan Communications 0207 466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE is listed on AIM (AGL.L); further informationcan be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer
7th Mar 20128:00 amRNSHolding(s) in the Company
28th Feb 201212:00 pmRNSDirector Share Transfer
28th Feb 20128:00 amRNSTotal Voting Rights
27th Feb 20127:00 amRNSParsortix Research Partnership
22nd Feb 20127:00 amRNSSecond Novocellus Patent
26th Jan 20127:00 amRNSInterim Results
26th Jan 20127:00 amRNSNovocellus Update
26th Jan 20127:00 amRNSFundraising
23rd Jan 20127:01 amRNSParsortix Update
19th Jan 20127:00 amRNSNotice of Interim Results and Webcast
16th Dec 20117:00 amRNSParsortix Update - Validation for Lung Cancer
7th Dec 20117:00 amRNSParsortix Update
21st Nov 20117:00 amRNSShare Options
16th Nov 20117:00 amRNSNovocellus Update
15th Nov 20117:00 amRNSIssue of equity and Total Voting Rights
11th Nov 20117:00 amRNSValidation for Prostate Cancer
10th Nov 20117:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.